'3 pufa' presentation slideshows

Omega-3 Fatty Acids : Naming, sources, intakes, metabolism and health benefits Philip Calder

Omega-3 Fatty Acids : Naming, sources, intakes, metabolism and health benefits Philip Calder Professor of Nutritional Immunology University of Southampton. This lecture will cover. Fatty acid structure, nomenclature, sources, and intakes

749 views • 44 slides

Nytta och risk med konsumtion av fet fisk Uppsala, okt.2002

443 views • 34 slides

Effects of n-3 PUFA in 6975 patients with chronic heart failure. The GISSI-HF trial

Effects of n-3 PUFA in 6975 patients with chronic heart failure. The GISSI-HF trial. Luigi Tavazzi on behalf of the GISSI-HF Investigators. GISSI-HF trial. Two nested studies to test:. N-3 polyunsaturated fatty acids hypothesis Rosuvastatin hypothesis in chronic HF patients.

657 views • 30 slides

Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF Trial

CLINICAL TRIAL UPDATE I. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF Trial.

448 views • 27 slides

The Food And Drink Innovation Network Omega-3 Seminar, Northamptonshire, 19 th Oct 2005

Healthy Claims. The Food And Drink Innovation Network Omega-3 Seminar, Northamptonshire, 19 th Oct 2005 Melanie Ruffell, Executive Director UK Joint Health Claims Initiative Food Industry Enforcement Consumers. Overview. JHCI background General principles for making healthy claims

414 views • 27 slides

1 INRA-URH, Research Centre of Clermont Fd/Theix, France,

318 views • 20 slides

1 INRA-URH, Research Centre of Clermont Fd/Theix, France,

321 views • 20 slides

Omega-3 Fatty Acid Composition of Habitual Diets in Australia

Omega-3 Fatty Acid Composition of Habitual Diets in Australia. Neil J Mann Department of Food Science. Melbourne Australia. Background. Generally agreed amongst lipid researchers that the western diet has: High n-6 : n-3 PUFA intake Low total n-3 PUFA intake

423 views • 19 slides

GISSI-HF: n-3 PUFA Study

GISSI-HF: n-3 PUFA Study. No difference between the two arms for primary endpoint (death), but significant difference noted on multivariate analysis ( HR 0.91, 95.5% CI 0.83-1.0; p = 0.041)

288 views • 1 slides